Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clascoterone vs Adapalene in Mild-to-Moderate Acne Vulgaris
NCT07883538Recruiting
- Sponsor
- Pak Emirates Military Hospital
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of clascoterone in acne vulgaris (2 arms), sponsored by Pak Emirates Military Hospital. Primary endpoint: Treatment Success based on Investigator's Global Assessment (IGA) at 12 weeks. Started Oct 2026; status: recruiting.
02
Drugs
clascoterone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT07883538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883538.